Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kyowa Hakko Kirin Seeks Wider Use Of Dialysis Anemia Drug

This article was originally published in PharmAsia News

Executive Summary

Japan's Kyowa Hakko Kirin applied to regulators to have its Nesp (darbepoetine) drug, now indicated for treating dialysis patients with renal anemia, also approved for cancer patients. Kyowa's application seeks approval for the drug in treating pre-dialysis patients and cancer patients who develop anemia following chemotherapy treatments. The company said it expects to get approval later this year and seesNesp as a successor to its Espo, which has a pre-dialysis indication. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts